Genomatica, Inc.

Genomatica, Inc. has been granted 155 US utility patents between 2015 and 2025, placing Genomatica, Inc. at rank #2,513 across all assignees tracked by PlainPatent. This portfolio spans 29 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.0 claims per patent with primary concentration in C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE). As a US Corporation, Genomatica, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 51.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 89 grants, compared with 66 in the 2015–2019 window — a +35% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Genomatica, Inc.'s 17.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 29 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Genomatica, Inc. against peers pursuing similar technology classes.